Drug Trial Radar · NCT06603220
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 14, 2024
Primary completion
May 8, 2025
Study completion May 8, 2025
Sponsor
- Lead sponsor
- Evommune, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Conditions
- Chronic Inducible Urticaria
Interventions
Oral EVO756 300 mg QDDrug
Oral EVO756, 300 mg once daily
Oral EVO756 50 mg BIDDrug
Oral EVO756 50 mg twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Day 1 to Week 6
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center, LLC
Birmingham, Alabama
California Allergy and Asthma Medical Group
Los Angeles, California
Integrative Skin Science and Research
Sacramento, California
West Dermatology Research Center
San Diego, California
Advanced Clinical Research Institute
Tampa, Florida
Aeroallergy Research Laboratories of Savannah, Inc.
Savannah, Georgia
Treasure Valley Medical Research
Boise, Idaho
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Southern Indiana Clinical Trials
New Albany, Indiana
Indiana Clinical Trials Center, P.C.
Plainfield, Indiana
DelRicht Research
Baton Rouge, Louisiana
Chesapeake Clinical Research, Inc
White Marsh, Maryland
OptiSkin Medical
New York, New York
Red River Research Partners
Fargo, North Dakota
Bexley Dermatology Research
Bexley, Ohio
Allergy, Asthma, and Clinical Research Center
Oklahoma City, Oklahoma
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania
Austin Institute for Clinical Research
Pflugerville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.